Congenital factor VII deficiency: Therapy with recombinant activated factor VII - A critical appraisal

Haemophilia

Volumn 12, Issue 1, 2006, Pages 19-27

  Mariani, G ^a   Konkle, B A ^b   Ingerslev, J ^c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c University Hospital   (Denmark)

Author keywords

Bleeding disorder; Congenital factor VII deficiency; NovoSeven; Recombinant factor VIIa; Substitution therapy

Indexed keywords

ALLOANTIBODY; ANTIBODY; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ACUTE DISEASE; AGE; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BRAIN HEMORRHAGE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EMERGENCY CARE; HEMOSTASIS; HUMAN; LICENSING; LUNG HEMORRHAGE; MEDICAL LITERATURE; PHLEBITIS; PRIORITY JOURNAL; PUBLISHING; REGISTER; THROMBOSIS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; EMERGENCIES; FACTOR VII; FACTOR VII DEFICIENCY; FEMALE; HEMORRHAGE; HEMOSTASIS; HUMANS; INFANT; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 33646013915     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01180.x     Document Type: Article

References (49)

1. Mariani G, Dolce A. Congenital factor VII deficiency. In: Lee C, Berntorp E, Hoots K, eds. Textbook of Hemophilia. Malden, MA, USA: Blackwell Publishing, 2005: 311-314.
2. Peyvandi F, Mannucci PM, Asti D, Abdoullahi M, Di Rocco N, Sharifian R. Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. Haemophilia 1997; 3: 242-6.
3. Ragni MV, Lewis JH, Spero JA, Hasiba U. Factor VII deficiency. Am J Hematol 1981; 10: 79-88.
4. Mariani G, Mazzucconi MG. Factor VII congenital deficiency. Clinical picture and classification of the variants. Haemostasis 1983; 13: 169-77.
5. Bauer KA. Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis 1996; 26 (Suppl. 1): 155-8.
6. McVey JH, Boswell E, Mumford AD, Kemball-Cook G, Tuddenham EG. Factor VII deficiency and the FVII mutation database. Hum Mutat 2001; 17: 3-17.
7. Tcheng WY, Donkin J, Konzal S, Wong WY. Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency. Haemophilia 2004; 10: 295-8.
8. Mariani G, Herrmann F, Dolce A et al. Clinical phenotypes and FVII genotypes in congenital factor VII deficiency. Thromb Haemost 2005; 93: 481-7.
9. Ingerslev J, Knudsen L, Hvid I, Tange MR, Fredberg U, Sneppen O. Use of recombinant factor VIIa in surgery in factor-VII-deficient patients. Haemophilia 1997; 3: 215-8.
10. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
11. Neuenschwander PF, Fiore MM, Morrissey JH. Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. J Biol Chem 1993; 268: 21489-92.
12. Ingerslev J, Kristensen HL. Clinical picture and treatment strategies in factor VII deficiency. Haemophilia 1998; 4: 689-96.
13. Wilde JT. Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors. Pathophysiol Haemost Thromb 2002; 32 (Suppl. 1): 9-12.
14. Mariani G, Herrmann FH, Schulman S et al. for the International Factor VII Deficiency Study Group. Thrombosis in inherited factor VII deficiency. J Thromb Haemost 2003; 1: 2153-8.
15. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; ; 2: 1700-8.
16. Billio A, Pescosta N, Rosanelli C, Amaddii G, Fontanella F, Coser P. Successful short-term oral surgery prophylaxis with rFVIIa in severe congenital factor VII deficiency. Blood Coagul Fibrinolysis 1997; 8: 249-50.
17. Eskandari N, Feldman N, Greenspoon JS. Factor VII deficiency in pregnancy treated with recombinant factor VIIa. Obstet Gynecol 2002; 99: 935-7.
18. Perry DJ. Factor VII deficiency. Br J Haematol 2002; 118: 689-700.
19. United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9: 1-23.
20. Berry EW, Teague L, Pitcher L, Ockelford P. NovoSeven® prophylaxis for severe FVII deficiency. Abstract from the Free-Paper Session and the Poster Session at the 6th Novo Nordisk Symposium on Treatment of Bleeding and Thrombotic Disorders. Copenhagen, Denmark, 3-4 May 2001. Denmark: Novo Nordisk A/S, 2001.
21. Mathijssen NCJ, Masereeuw R, Verbeek K et al. Prophylactic effect of recombinant factor VIIa in factor VII deficient patients. Br J Haematol 2004; 125: 494-9.
22. Muleo G, Santoro R, Iannaccaro P et al. rFVIIa in congenital FVII deficiency. Thromb Res 1998; 91 (Suppl. 1): S86. Abstract 169.
23. Recht M, Holve S, Stuart R, Hu D, Moul S. Prophylaxis of bleeding using recombinant factor VIIa in an infant with severe, congenital factor VII deficiency. Pediatr Res 2002; 51 (Pt 2): 260A. Abstract 1514.
24. Halsey C, Singer JD, Manning R, Laffan M, Layton M. The use of prophylactic recombinant factor VII to prevent intracranial haemorrhage in an infant with severe factor VII deficiency. Br J Haematol 2002; 117 (Suppl. 1): 11-2. Abstract 31.
25. Salameh MM, Banda RW, El Ali M. Spontaneous intracranial hemorrhage due to congenital factor VII deficiency in two term siblings: Treatment with activated recombinant factor VII (rFVIIa). Thromb Haemost 1997 ; 13 (Suppl. 12): Abstract PS-47.
26. Muleo G, Santoro R, Iannaccaro PG, Papaleo P, Leo F. The use of recombinant activated factor VII in congenital and acquired factor VII deficiencies. Blood Coagul Fibrinolysis 1998; 9: 389-90.
27. Jiménez-Yuste V, Villar A, Morado M et al. Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency. Haemophilia 2000; 6: 588-90.
28. Holve S, Stuart R, Recht M. Prophylaxis of recurrent epistaxis and menorrhagia using recombinant factor VIIa in severe, congenital factor VII deficiency. Pediatr Res 2001; 49 (Pt 2): 203A. Abstract 1154.
29. Karayalcin G, Hart D. Prophylaxis with rFVIIa in a pediatric patient with severe factor VII deficiency. Pediatr Res 2002; 51 (Pt 2): 259 -60A. Abstract 1509.
30. White B, O'Connor H, Smith OP. Successful use of recombinant VIIa (Novoseven®) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency. Blood Coagul Fibrinolysis 2000; 11: 155-7.
31. Hirawat S, Assael N, Allen SL. Recombinant factor VIIa prophylaxis for a patient with severe factor VII deficiency undergoing dental extraction. Bone Marrow Transplant 2000; 96 (Pt 2): 84b. Abstract 4042.
32. Lohar PV, Coyle TE, Khan S. Successful inguinal herniorraphy in a patient with congenital factor VII deficiency using recombinant factor VIIa concentrate (Novoseven). Blood 2000; 96 (Pt 2): 86b. Abstract 4051.
33. Dicato MA, Schmit A, Berchem G, Duhem C, Ries F. In a congenital factor VII (FVII) deficient patient amniocentesis with recombinant FVII (rhFVII) was easily performed. Surveillance by prothrombin time is very satisfactory. Bone Marrow Transplant 2000; 96 (Pt 2): 81b. Abstract 4031.
34. Ingerslev J, Christiansen K, Sørensen B. For the International Registry on Factor VII Deficiency (IRF7) Steering Committee. Inhibitor to factor VII in severe factor VII deficiency: Detection and course of the inhibitory response. J Thromb Haemost 2005; 3: 799-800.
35. Rice KM, Savidge GF. NovoSeven® (recombinant factor VIIa) in central nervous system bleeds. Haemostasis 1996; 26 (Suppl. 1): 131-4.
36. Bech RM. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996; 26 (Suppl. 1): 135-8.
37. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999; 5: 253-9.
38. Cobos E, Keung YK, Akhter S, Jones J. Use of recombinant factor VIIa for major elective surgery in a patient with factor VII deficiency, retroperitoneal fibrosis and hydronephrosis. Clin Appl Thromb Hemost 1997; 3: 33-5.
39. Bergmann F, Scharrer I. Transient factor VII inhibitor after replacement therapy with recombinant FVIIa (rFVIIa) in a child with FVII deficiency. Bone Marrow Transplant 1998; 92 (Suppl. 1 Pt 1-2): 104b. Abstract 3430.
40. Mariani G, Testa MG, Di Paolantonio T, Molskov Bech R, Hedner U. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999; 77: 131-6.
41. Wong WY, Huang WC, Miller R, McGinty K, Whisnant JK. Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia 2000; 6: 50-4.
42. Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S119-23.
43. Rothschild C, Scharrer I, Brackmann HH et al. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients. Haemophilia 2002; 8 (Suppl. 2): 10-4.
44. Yoshioka A, Fukutake K, Takamatsu J, Shirahata A, for the Kogenate Post-Marketing Surveillance Study Group. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A. Int J Hematol 2003; 78: 467-74.
45. Lusher JM, Lee CA, Kessler CM, Bedrosian CL, for the ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
46. Lusher J, Abildgaard C, Arkin S et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: Final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 574-83.
47. Hay CRM. Thrombosis and recombinant factor VIIa. J Thromb Haemost 2004; 2: 1698-9 (Commentary).
48. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-12.
49. Mariani G, Dolce A. Congenital factor VII deficiency. In: Lee C, Berntorp E, Hoots K, eds. Textbook of Hemophilia. Malden, MA, USA: Blackwell Publishing, 2005: 311-314.